---
title: Next Generation Ophthalmic Irrigating Solution Posterior Segment Study
nct_id: NCT00333203
overall_status: COMPLETED
phase: PHASE3
sponsor: Alcon Research
study_type: INTERVENTIONAL
primary_condition: Eye Diseases
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00333203.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00333203"
ct_last_update_post_date: 2012-03-05
last_seen_at: "2026-05-12T07:02:30.013Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Next Generation Ophthalmic Irrigating Solution Posterior Segment Study

**Official Title:** Clinical Evaluation of the Safety of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus for Use During Surgery for Removal of Epimacular Membrane and Vitrectomy

**NCT ID:** [NCT00333203](https://clinicaltrials.gov/study/NCT00333203)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 369
- **Lead Sponsor:** Alcon Research
- **Conditions:** Eye Diseases
- **Start Date:** 2005-10
- **Completion Date:** 2006-03
- **CT.gov Last Update:** 2012-03-05

## Brief Summary

The purpose of this study is to evaluate the safety of Next Generation Ophthalmic Irrigating Solution (NGOIS) compared to BSS PLUS for use during surgery for removal of epimacular membrane and vitrectomy.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients of any race and sex, with an epimacular membrane who would benefit from vitrectomy and membrane removal.
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Under 18 years of age.
* Other protocol-defined exclusion criteria may apply.
```

## Arms

- **NGOIS** (EXPERIMENTAL)
- **BSS Plus** (ACTIVE_COMPARATOR)

## Interventions

- **Next Generation Ophthalmic Irrigating Solution (NGOIS)** (DRUG) — Volume sufficient to irrigate adequately during cataract surgery
- **BSS Plus** (OTHER) — Volume sufficient to irrigate adequately during cataract surgery

## Primary Outcomes

- **Best-corrected logMAR visual acuity**

## Secondary Outcomes

- **Intraocular pressure (IOP)**

## Locations (1)

- United States, Fort Worth, Texas, United States

## Recent Field Changes (last 30 days)

- `results.hasResults` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `locations.united states|fort worth|texas|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00333203.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00333203*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*